|
1
|
Olesen J and Steiner TJ: The International
classification of headache disorders, 2nd edn (ICDH-II). J Neurol
Neurosurg Psychiatry. 75:808–811. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Katusic S, Beard CM, Bergstralth E and
Kurland LT: Incidence and clinical features of trigeminal
neuralgia, Rochester, Minnesota, 1945–1984. Ann Neurol. 27:89–95.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ngeow WC and Nair R: Injection of
botulinum toxin type A (BOTOX) into trigger zone of trigeminal
neuralgia as a means to control pain. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. 109:e47–e50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Devor M, Amir R and Rappaport ZH:
Pathophysiology of trigeminal neuralgia: The ignition hypothesis.
Clin J Pain. 18:4–13. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheshire WP: Trigeminal neuralgia: For one
nerve a multitude of treatments. Expert Rev Neurother. 7:1565–1579.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Merrison AF and Fuller G: Treatment
options for trigeminal neuralgia. BMJ. 327:1360–1361. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Castillo-Alvarez F, Hernando de la Barcena
I and Marzo-Sola ME: Botulinum toxin in trigeminal neuralgia. Med
Clin (Barc). 148:28–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Humeau Y, Doussau F, Grant NJ and Poulain
B: How botulinum and tetanus neurotoxins block neurotransmitter
release. Biochimie. 82:427–446. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pearce LB, First ER, Maccallum RD and
Gupta A: Pharmacologic characterization of botulinum toxin for
basic science and medicine. Toxicon. 35:1373–1412. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lian YJ, Wei HL, Zhang BA, et al:
Treatment of 795 facial spasm and local dystonia with Botulinum
toxin A. J Zhengzhou Univ (Med Sci). 44:32009.
|
|
11
|
Aurora SK, Winner P, Freeman MC, Spierings
EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME and Turkel CC:
OnabotulinumtoxinA for treatment of chronic migraine: Pooled
analyses of the 56-week PREEMPT clinical program. Headache.
51:1358–1373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Diener HC, Dodick DW, Aurora SK, Turkel
CC, DeGryse RE, Lipton RB, Silberstein SD and Brin MF; PREEMPT 2
Chronic Migraine Study Group, : OnabotulinumtoxinA for treatment of
chronic migraine: Results from the double-blind, randomized,
placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia.
30:804–814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Micheli F, Scorticati MC and Raina G:
Beneficial effects of botulinum toxin type a for patients with
painful tic convulsif. Clin Neuropharmacol. 25:260–262. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu CJ, Lian YJ, Zheng YK, Zhang HF, Chen
Y, Xie NC and Wang LJ: Botulinum toxin type A for the treatment of
trigeminal neuralgia: Results from a randomized, double-blind,
placebo-controlled trial. Cephalalgia. 32:443–450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu Y, Guan X, Fan L, Li M, Liao Y, Nie Z
and Jin L: Therapeutic efficacy and safety of botulinum toxin type
A in trigeminal neuralgia: A systematic review. J Headache Pain.
14:722013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morra ME, Elgebaly A, Elmaraezy A, Khalil
AM, Altibi AM, Vu TL, Mostafa MR, Huy NT and Hirayama K:
Therapeutic efficacy and safety of botulinum toxin a therapy in
trigeminal neuralgia: A systematic review and meta-analysis of
randomized controlled trials. J Headache Pain. 17:632016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Headache Classification Subcommittee of
the International Headache Society, . The International
Classification of Headache Disorders: 2nd edition. Cephalalgia. 24
(Suppl 1):S9–S160. 2004.
|
|
18
|
Lee JS: Pain measurement: Understanding
existing tools and their application in the emergency department.
Emerg Med (Fremantle). 13:279–287. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ross I and Robert G: R: A language for
data analysis and graphics. J Computational Graphical Statistics.
5:299–314. 1996. View Article : Google Scholar
|
|
20
|
Zakrzewska JM: Botulinum toxin type A for
trigeminal neuralgia-we have the prima facie evidence. Cephalalgia.
32:1156–1157. 2012. View Article : Google Scholar
|
|
21
|
Zhang H, Lian Y, Ma Y, Chen Y, He C, Xie N
and Wu C: Two doses of botulinum toxin type A for the treatment of
trigeminal neuralgia: Observation of therapeutic effect from a
randomized, double-blind, placebo-controlled trial. J Headache
Pain. 15:652014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li S, Lian YJ, Chen Y, Zhang HF, Ma YQ, He
CH, Wu CJ, Xie NC, Zheng YK and Zhang Y: Therapeutic effect of
botulinum toxin-a in 88 patients with trigeminal neuralgia with
14-month follow-up. J Headache Pain. 15:432014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen JH, Lian YJ and Zheng YK: Effect of
botulinum toxin type a on clssic trigeminal neuralgia. Chin J Rehab
Med. 26:22011.
|
|
24
|
Fabregat G, De Andrés J, Villanueva-Pérez
VL and Asensio-Samper JM: Subcutaneous and perineural botulinum
toxin type A for neuropathic pain: A descriptive review. Clin J
Pain. 29:1006–1012. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Klein AW: The therapeutic potential of
botulinum toxin. Dermatologic Surgery. 30:452–455. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Aoki KR: Review of a proposed mechanism
for the antinociceptive action of botulinum toxin type A.
Neurotoxicology. 26:785–793. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gazerani P, Pedersen NS, Staahl C, Drewes
AM and Arendt-Nielsen L: Subcutaneous Botulinum toxin type A
reduces capsaicin-induced trigeminal pain and vasomotor reactions
in human skin. Pain. 141:60–69. 2009. View Article : Google Scholar : PubMed/NCBI
|
